HIGHLIGHTS

1 Selected Articles from This Issue

SPECIAL FEATURES

CCR Translations

3 CDK4/6 Inhibitor Biomarker Research: Are We Barking Up the Wrong Tree?
Meenakshi Anurag, Svasti Haricharan, and Matthew J. Ellis
See related article, p. 110

6 Metabolic Subtyping for Novel Personalized Therapies Against Pancreatic Cancer
Kamiya Mehla and Pankaj K. Singh
See related article, p. 135

9 A Solution to the Dilution: The Role for Biomarkers in Advanced Ovarian Cancer
Katelyn F. Handley and Anil K. Sood
See related article, p. 213

Review

11 Immune Activation in Mismatch Repair–Deficient Carcinogenesis: More Than Just Mutational Rate
Jason A. Willis, Laura Reyes-Urbe, Kyle Chang, Steven M. Lipkin, and Eduardo Vilar

CLINICAL TRIALS: TARGETED THERAPY

18 Clinical Assessment of 5-Fluorouracil/Leucovorin, Nab-Paclitaxel, and Irinotecan (FOLFIRABRAX) in Untreated Patients with Gastrointestinal Cancer Using UGT1A1 Genotype–Guided Dosing

25 Selective Progesterone Receptor Modulators in Early-Stage Breast Cancer: A Randomized, Placebo-Controlled Phase II Window-of-Opportunity Trial Using Telapristone Acetate

35 Randomized Phase 0/1 Trial of the Mitochondrial Inhibitor ME-344 or Placebo Added to Bevacizumab in Early HER2-Negative Breast Cancer
Miguel Quintela-Fandino, Serafín Morales, Alfonso Cortés-Salgado, Luis Manso, Juan V. Apala, Manuel Muñoz, Ariadna Gasol Cudos, Joel Salla Fortuny, María Gion, Antonio López-Alonso, Javier Cortés, Juan Guerra, Diego Malón, Eduardo Calciras, Francisca Mulero, and Silvana Mouron

46 Extended 5-Year Follow-up Results of a Phase Ib Study (BRIM7) of Vemurafenib and Cobimetinib in BRAF-Mutant Melanoma
Antoni Ribas, Adil Daud, Anna C. Pavlick, Rene Gonzalez, Karl D. Lewis, Omid Hamid, Thomas F. Gajewski, Isabelle Rooney, Jesse J. Hsu, Yiping Yan, Erica Park, and Grant A. McArthur

54 Phase I Clinical Trial of Selinexor in Combination with Daunorubicin and Cytarabine in Previously Untreated Poor-Risk Acute Myeloid Leukemia
TABLE OF CONTENTS

CLINICAL TRIALS: IMMUNOTHERAPY

61 Efficacy and Tolerability of Tremelimumab in Locally Advanced or Metastatic Urothelial Carcinoma Patients Who Have Failed First-Line Platinum-Based Chemotherapy

Padmanee Sharma, Joohyuk Sohn, Sang Joon Shin, Do-Youn Oh, Bhumsuk Keam, Hyo Jin Lee, Marco Gizz, Ewa Kalinka, Filip Y.F.L. de Vos, Dario Ruscica, Salvatore Ferro, Feng Xiao, Paul Baurel, Ceci Chi-Keung Chen, Kobby Asubonteng, Nassim Morsli, and Luc Dirix

71 Pembrolizumab in Combination with the Oncolytic Virus Pelareorep and Chemotherapy in Patients with Advanced Pancreatic Adenocarcinoma: A Phase Ib Study

Devalingam Mahalingam, Grey A. Wilkinson, Kevin H. Eng, Paul Fields, Patrick Raber, Jennifer L. Moseley, Karol Cheetham, Matt Coffey, Gerard Nuovo, Pawel Kalinski, Bin Zhang, Sukeshi Patel Arora, and Christos Fountzilas

PRECISION MEDICINE AND IMAGING

82 Purity Independent Subtyping of Tumors (PIrST), A Clinically Robust, Single-sample Classifier for Tumor Subtyping in Pancreatic Cancer


93 DNA Methylation Profiling Identifies Distinct Clusters in Angiosarcomas


101 Sex Disparity Observed for Oncotype DX Breast Recurrence Score in Predicting Mortality Among Patients with Early Stage ER-Positive Breast Cancer

Fei Wang, Sony Reid, Wei Zheng, Tuya Pal, Ingrid Meszoely, Ingrid A. Mayer, Christina E. Bailey, Ben Ho Park, and Xiao-You Shu

110 Biomarker Analyses of Response to Cyclin-Dependent Kinase 4/6 Inhibition and Endocrine Therapy in Women with Treatment-Naive Metastatic Breast Cancer

Richard S. Finn, Yuan Liu, Zhou Zhu, Miguel Martin, Hope S. Rugo, Véronique Diéras, Seock-Ah Im, Karen A. Gelmon, Nadia Harbeck, Dongru L. Lu, Eric Gauthier, Cynthia Huang Bartlett, and Dennis J. Slamon

See related commentary, p. 3

122 Detection of Circulating and Disseminated Neuroblastoma Cells Using the ImageStream Flow Cytometer for Use as Predictive and Pharmacodynamic Biomarkers

Swarthi Merugu, Lindi Chen, Elizabeth Gavens, Hany Gabra, Mark Brougham, Guy Makin, Antony Ng, Dermot Murphy, Alem S. Gabriel, Michael L. Robinson, Jennifer H. Wright, Susan A. Burchill, Angharad Humphreys, Nick Bown, David Jamieson, and Deborah A. Tweedle

135 Altered Gene Expression along the Glycolysis–Cholesterol Synthesis Axis Is Associated with Outcome in Pancreatic Cancer


See related commentary, p. 6

147 Ultrasound Core-Shell Silica Nanoparticles for Precision Drug Delivery in a High-Grade Malignant Brain Tumor Model

Rupa Juthani, Brian Madajewski, Barney Yoo, Li Zhang, Pei-Ming Chen, Feng Chen, Melik Z. Turker, Kai Ma, Michael Overholtza, Valerie A. Longoa, Sean Carlin, Virginia Aragon-Sanabria, Jason Huse, Mithat Gonen, Pat Zanizonico, Charles M. Rudin, Ulrich Wiesner, Michelle S. Bradbury, and Cameron W. Brennan

159 A Transcriptionally Definable Subgroup of Triple-Negative Breast and Ovarian Cancer Samples Shows Sensitivity to HSP90 Inhibition

Kevin Shee, Jason D. Wells, Matthew Ung, Riley A. Hampsch, Nicole A. Traphagen, Wei Yang, Stephanie C. Liu, Megan A. Zeldenrust, Liwei Wang, Krishna R. Kalari, Jia Yu, Judy C. Bougher, Eugene Demidenko, Armija N. Kettenbach, Chao Cheng, Matthew P. Goetch, and Todd W. Miller

171 Comprehensive Transcriptomic Profiling Identifies Breast Cancer Patients Who May Be Spared Adjuvant Systemic Therapy

Martin Sjöström, S. Laura Chang, Nick Fishbane, Elai Davicinoni, Linda Hartman, Erik Holmberg, Felix Y. Feng, Corey W. Speers, Lori J. Pierce, Per Malmström, Martin Fourné, and Per Karlsson

Downloaded from clincancerres.aacrjournals.org on June 16, 2021. © 2020 American Association for Cancer Research.
TABLE OF CONTENTS

301  A PI3K/AKT Scaffolding Protein, IQ Motif-Containing GTPase Associating Protein 1 (IQGAP1), Promotes Head and Neck Carcinogenesis

Tao Wei, Suyong Choi, Darya Buehler,
Richard A. Anderson, and Paul F. Lambert

EDITOR'S NOTE

312  Editor's Note: Sulforaphane Enhances the Therapeutic Potential of TRAIL in Prostate Cancer Orthotopic Model through Regulation of Apoptosis, Metastasis, and Angiogenesis

Sharmila Shankar, Suthakar Ganapathy, and Rakesh K. Srivastava

313  Acknowledgment to Reviewers

ABOUT THE COVER

The cover shows a section of the tumor core of a patient with pancreatic cancer. Immunofluorescence staining with ki67 shows the proliferating cells within the tumor on primarily resected patients. For details, see the article by Mota Reyes and colleagues on page 220 of this issue.